Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer

scientific article published on 25 August 2018

Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.IJROBP.2018.08.027
P698PubMed publication ID30149056

P50authorHong WangQ37610192
P2093author name stringDwight E Heron
David A Clump
Steven A Burton
Ronny Kalash
Daniel P Petro
Philip Sutera
David D'Ambrosio
Alina Mihai
P433issue1
P921main subjectphase II clinical trialQ42824440
multicenter clinical trialQ6934595
P304page(s)116-122
P577publication date2018-08-25
P1433published inInternational Journal of Radiation Oncology Biology PhysicsQ2296252
P1476titleInitial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer
P478volume103

Reverse relations

cites work (P2860)
Q92747874Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer
Q64055804Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer
Q93129302NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
Q90706179Oligometastatic head and neck cancer: Comprehensive review
Q64063425Peripheral memory and naïve T cells in non-small cell lung cancer patients with lung metastases undergoing stereotactic body radiotherapy: predictors of early tumor response
Q89520971Signals from SABR-COMET time to move on to phase III studies
Q104693486Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
Q100573253Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers
Q92605873The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer

Search more.